Trials / Unknown
UnknownNCT01990092
The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Nutritional Benefits of Metanx® in Subjects With Diabetic Peripheral Neuropathy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 238 (actual)
- Sponsor
- Pamlab, Inc. · Industry
- Sex
- All
- Age
- 25 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of the MEDIAN study are to evaluate the short-term and long-term safety and nutritional benefits of Metanx® versus placebo in subjects with mild to moderate diabetic peripheral neuropathy (DPN). Short-term effects will be evaluated during the first 16 weeks of treatment, and long-term effects will be evaluated over the duration of a 48 week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Metanx | Metanx is a prescription medical food. |
| OTHER | Placebo |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2016-08-01
- Completion
- 2018-03-01
- First posted
- 2013-11-21
- Last updated
- 2016-01-18
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01990092. Inclusion in this directory is not an endorsement.